---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059491"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:03:57.622614+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Korro Bio Q1 net loss $19.6M; appoints Kemi Olugemo as CMO; cash $138.8M plus $70M PIPE

## Summary
- Net loss $19.6M in Q1 2024, unchanged from Q1 2023; R&D $13.6M, G&A $7.9M.
- Cash $138.8M at Mar 31, 2024; after $70M April PIPE, pro forma ~$206M; runway into H2 2026.
- Appointed Kemi Olugemo, MD, as Chief Medical Officer; she brings >10 yrs industry experience.
- Regulatory filing for KRRO-110 (RNA editing for AATD) on track for H2 2024; interim data H2 2025.
- $70M PIPE led by Deep Track Capital with Atlas Venture, NEA, and other healthcare investors.

## SEC filing metadata
- accession: 0000950170-24-059491
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000095017024059491/0000950170-24-059491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000095017024059491/krro-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059491
- JSON: https://secwatch.observer/filing/0000950170-24-059491.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059491.txt

## Key facts
- Earnings Releases
  Korro Bio, Inc. reported first quarter of 2024 results: net income $19.6 million.
  - Period: first quarter of 2024
  - Net income: $19.6 million
  - Result: reported results
  source text: Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000095017024059491/0000950170-24-059491-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.